机构：[1]Guangdong Lung Cancer Institute, Guangdong Provincial People’s Hospital, Guangzhou, China广东省人民医院[2]Guangdong Lung Cancer Institute, Guangdong Provincial People’s Hospital, Guangzhou, China广东省人民医院[3]Department of Internal Medicine for Lung Cancer, Affiliated Tumor Hospital of Guangxi Medical University, Nanning, China[4]Department of Oncology, The First Affiliated Hospital of Guangxi Medical University, Nanning, China[5]Department of Oncology, The First Affiliated Hospital of Guangzhou University of Chinese Medicine, Guangzhou, China[6]Department of Oncology, Binzhou Medical University Hospital, Binzhou, China[7]Cancer Center, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China华中科技大学同济医学院附属协和医院[8]Department of Thoracic Oncology, Fujian Cancer Hospital, Fuzhou, China[9]Department of Oncology, Affiliated Hospital of Hebei University / School of Clinical Medicine, Baoding, China河北大学附属医院[10]Department of Thoracic Oncology, Affiliated Hangzhou Cancer Hospital, Zhejiang University School of Medicine, Hangzhou, China[11]Department of Respiratory, The First Affiliated Hospital of Guangzhou Medical University, Guangzhou, China[12]Department of Oncology, The Second Affiliated Hospital of Nanchang University, Nanchang, China[13]Department of Oncology, Zhongda Hospital Southeast University, Nanjing, China[14]Department of Oncology, The First Affiliated Hospital of Xi’an Jiaotong University, Xi’an, China[15]Department of Radiation Oncology, Hubei Cancer Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China[16]Department of Thoracic Oncology, Beijing Cancer Hospital, Beijing, China[17]Department of Medical Affairs, Jiangsu Hengrui Pharmaceuticals Co., Ltd., Shanghai, China
Background: Retrospective studies suggest benefits of immunotherapy plus radiotherapy for brain metastases (BM) in NSCLC. CTONG 2003 is the first RCT to assess
first-line camrelizumab versus placebo for BM in NSCLC.
第一作者机构：[1]Guangdong Lung Cancer Institute, Guangdong Provincial People’s Hospital, Guangzhou, China
推荐引用方式(GB/T 7714)：
Yang J-j.,Li Y.,Yu Q.,et al.First-line camrelizumab plus chemotherapy for brain metastases in NSCLC: The CTONG 2003 randomized controlled trial[J].ANNALS OF ONCOLOGY.2024,35:doi:10.1016/j.annonc.2024.10.699.
APA：
Yang, J-j.,Li, Y.,Yu, Q.,Bu, Q.,Lin, L....&Wu, Y-l..(2024).First-line camrelizumab plus chemotherapy for brain metastases in NSCLC: The CTONG 2003 randomized controlled trial.ANNALS OF ONCOLOGY,35,
MLA：
Yang, J-j.,et al."First-line camrelizumab plus chemotherapy for brain metastases in NSCLC: The CTONG 2003 randomized controlled trial".ANNALS OF ONCOLOGY 35.(2024)
医学